Department of Pharmacy, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Department of Pathology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Front Immunol. 2022 Dec 1;13:1038715. doi: 10.3389/fimmu.2022.1038715. eCollection 2022.
Lung cancer (LC) and chronic obstructive pulmonary disease (COPD) are two of the most fatal respiratory diseases, seriously threatening human health and imposing a heavy burden on families and society. Although COPD is a significant independent risk factor for LC, it is still unclear how COPD affects the prognosis of LC patients, especially when LC patients with COPD receive immunotherapy. With the development of immune checkpoint inhibition (ICI) therapy, an increasing number of inhibitors of programmed cell death-1 (PD-1) and PD-1 ligand (PD-L1) have been applied to the treatment of LC. Recent studies suggest that LC patients with COPD may benefit more from immunotherapy. In this review, we systematically summarized the outcomes of LC patients with COPD after anti-PD-1/PD-L1 treatment and discussed the tumor immune microenvironment (TIME) regulated by COPD in LC immunotherapy, which provides novel insights for the clinical treatment of LC patients with COPD.
肺癌 (LC) 和慢性阻塞性肺疾病 (COPD) 是两种最致命的呼吸系统疾病，严重威胁着人类健康，给家庭和社会带来沉重负担。虽然 COPD 是 LC 的一个重要独立危险因素，但目前尚不清楚 COPD 如何影响 LC 患者的预后，尤其是当 LC 合并 COPD 的患者接受免疫治疗时。随着免疫检查点抑制 (ICI) 治疗的发展，越来越多的程序性细胞死亡蛋白-1 (PD-1) 和 PD-1 配体 (PD-L1) 的抑制剂已被应用于 LC 的治疗。最近的研究表明，合并 COPD 的 LC 患者可能从免疫治疗中获益更多。在这篇综述中，我们系统地总结了抗 PD-1/PD-L1 治疗后合并 COPD 的 LC 患者的结局，并讨论了 COPD 调节的 LC 免疫治疗中的肿瘤免疫微环境 (TIME)，为合并 COPD 的 LC 患者的临床治疗提供了新的见解。
